Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | C5 | P01031 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29858584 | 1.00 | LMNA (0.55) | LMNATP53HTTMEN1KMT2A | |
| SCHEMBL15641246 | 1.00 | LMNA (0.55) | LMNATP53HTTMEN1KMT2A | |
| SCHEMBL13235897 | 0.89 | LMNA (0.55) | LMNATP53HTTMEN1KMT2A | |
| SCHEMBL27671813 | 0.86 | LMNA (0.57) | LMNATP53HTTMEN1KMT2A | |
| SCHEMBL2110334 | 0.85 | TP53 (0.47) | LMNATP53HTTMEN1KMT2A | |
| SCHEMBL31276823 | 0.85 | TP53 (0.47) | LMNATP53HTTMEN1KMT2A | |
| SCHEMBL7820665 | 0.83 | LMNA (0.58) | LMNATP53HTTMEN1KMT2A | |
| SCHEMBL10745903 | 0.83 | TSHR (0.54) | LMNATP53HTTMEN1KMT2A | |
| SCHEMBL10745986 | 0.83 | CXCL8 (0.43) | LMNAMEN1KMT2APTGS2PTGS1 | |
| SCHEMBL27697380 | 0.83 | PTGS2 (0.45) | LMNATP53HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160285-A | Thioamides ALDH 2 Agonist, preparation method and application | 云南大学 | 2022-10-11 | — | — | CN | disclosed |
| WO-2018140339-A1 | AMIDE COMPOUNDS AND USE THEREOF | ALPHALA CO., LTD. (TW) | 2018-08-02 | — | — | WO | disclosed |
| US-9688680-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688680-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688680-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2017-06-27 | — | — | US | disclosed |
| EP-2734526-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-04-06 | — | — | EP | disclosed |
| WO-2016022569-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016022569-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2016-02-11 | — | — | WO | disclosed |
| US-20160031892-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2016-02-04 | — | — | US | disclosed |
| US-20160031892-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2016-02-04 | — | — | US | disclosed |
| WO-1996040656-A1 | NOVEL N-(2,4-DIOXO-2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPIN-3YL)-3-AMIDES | MERCK & CO., INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040653-A1 | NOVEL N-(1-ALKYL-5-PHENYL-2,3,4,5-TETRAHYDRO-1H-BENZO[B][1,4]DIAZEPIN-3-YL)-ACETAMIDES | MERCK & CO., INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0730581-A1 | 3-ACYLAMINOBENZAZEPINES | MERCK & CO. INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0730453-A1 | METHODS OF TREATING CARDIAC ARRHYTHMIA | MERCK & CO. INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5428031-A | Benzodiazepine analogs; cardiovascular disorders | MERCK & CO., INC. (US) | 1995-06-27 | — | — | US | disclosed |
| WO-1995014671-A1 | 3-ACYLAMINOBENZAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995014470-A1 | METHODS OF TREATING CARDIAC ARRHYTHMIA | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| US-5047518-A | 1,6-anhydro-β-hexopyranose derivatives and their use as herbicides and plant growth regulators | HER MAJESTY THE QUEEN IN RIGHT OF NEW ZEALAND (NZ) | 1991-09-10 | — | — | US | disclosed |
| EP-0302599-A2 | Bicyclo-octane and bicyclo-nonane derivatives, processes for their preparation and their use as herbicides | HER MAJESTY THE QUEEN IN RIGHT OF NEW ZEALAND, DEPARTMENT OF SCIENTIFIC AND INDUSTRIAL RESEARCH, CHEMISTRY DIVISON (NZ) | 1989-02-08 | — | — | EP | disclosed |
| EP-0229034-A2 | Hexopyranoses and compositions for agricultural use | HER MAJESTY THE QUEEN in right of New Zealand Department of Scientific and Industrial Research (NZ) | 1987-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031892-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, CKMT1A; CKMT1B | LMNA 429/4885TP53 541/4885HTT 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.